Novo's Victoza Diabetes Medicine Rebuffed by Express Scripts

Novo's Victoza Diabetes Medicine Rebuffed by Express Scripts

This post was originally published on this site
Novo Nordisk A/S’s Victoza, a diabetes treatment that dominates its class of drugs, was shunned by U.S. pharmacy benefits manager Express Scripts Holding Co. for at least the second year in a row, suggesting that the Danish company refused to concede on its pricing.

Start the conversation, or Read more at The Washington Post.